Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.9 USD | +3.25% | +14.10% | +505.44% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Evolution of the average Target Price on Candel Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Candel Therapeutics, Inc.
Credit Suisse | |
UBS | |
HC Wainwright | |
BMO Capital | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- CADL Stock
- Consensus Candel Therapeutics, Inc.